FDA Accepts NDA Of Onglyza In Combination With Extended Release Metformin
Onglyza has been submitted for regulatory review in more than 50 countries and is approved in 38 countries, including the US and member states of the EU. Onglyza
ReviR Therapeutics has received a rare paediatric disease designation (RPDD) from the US Food and Drug Administration (FDA) for RTX-117, its investigational oral small-molecule therapy for Charcot-Marie-Tooth disease (CMT).
Emisphere’s drug delivery platform, known as the Eligen Technology, uses proprietary, synthetic carriers to enhance the oral bioavailability of a drug without altering its chemical form or biological
The BD Protect system, designed by CDC-trained epidemiologists, addresses multiple issues confronting healthcare administrators and public health officers, including the transmission of multidrug-resistant organisms in healthcare settings and